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A bstract
O bjective: Radiation O ncology practices can exhibit heterogeneities betw een and som etim es w ithin 
institutions. C linical registries w ith  scope and detail could quantify  consistency and distinctives that justify  
difference. R etrospective, isolated clinical audits are problem atic, typ ically  because no t all data are captured 
in charts, w hile useful prospective clinical registries w ill have to be practical, efficient and accurate. We 
tested feasibility  o f  a clinical registry  at a critical tim e-point in the patient's clin ical trajectory w hen treating 
physicians could have requisite data.
D esign:  This w as a prospective and non-random ized observational study. Four centres used  a 1 -page form  to 
acquire data during a 4-m onth  period. Patients had curative breast, rectum  o r prostate cancers, or w ere 
palliative. O bjectives w ere to dem onstrate form  com pletion and to  delineate patterns o f  disease presentation 
and clinical practice.
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R esu lts:  The 107 cases had 99%  com plete data, internally consistent w ithin cases and centres. Similar 
practices w ere seen for 22 cases with curative rectal and prostate cancer, and 34 palliative cases, but o f  the 51 
curative breast cancer cases those in A frica w ere with greater Stage, underw ent m ore extensive surgery, were 
less likely to receive shorter radiation schedules, and w ere less exposed to Taxane-based chem otherapy 
regim ens.
C onclusions:  This study dem onstrates the feasibility  for a sim ple clinical registry  requiring m inim al effort by 
participants. A  real-tim e pan-A frican registry, operating continually  or in regular w aves, could provide 
im portant know ledge at little cost.
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Introduction
Cancer is a major disease category in higher-income 
countries (HIC), In HIC, health resources are 
substantial, with budgets for health care exceeding 
10% of Gross Domestic Product of large economies. 
This resourcing is many times higher1 than that in low- 
and-middle-income countries (LMIC) where there are 
fewer infrastructures2 and less political and socio­
cultural support.24 However, cancer is an increasing 
concern in LMIC's due to improving longevity and the 
changing prevalences of etiological agents and broader 
determinants of disease. 2 6 Indeed, global mortality 
from cancer exceeds that from tuberculosis, malaria 
and HIV-AIDS combined2, and there are many more 
cancer cases in LMIC than in HIC. ’
How best to martial and allocate resources to obtain 
cancer control in LMIC remains to be determined.1’1 
In developed countries, budget allocations and clinical 
policies are typically well-established and are based on 
research done at leading “Western” institutions. In 
contrast, research in LMIC lags2 with too few loco- 
regional data to inform practice and decision-making.4 
Consequently, there is persistent debate about whether 
“Western” research is directly applicable to LMIC 
contexts (e.g. ICARO, 200912; AFRA 2006lj and 
201014). For example, LMIC cases may have more 
advanced Stages, and be less tolerant to some 
aggressive treatments (due to greater co-morbidities, or 
genomic and nutritional factors), and there may be 
different economic, socio-culturai and clinical 
imperatives.’4 Differences between countries should 
modify strategies for cancer control. But are these 
differences large enough, or sufficiently categorical, to 
be distinctives, so that “Western medicine and trials are 
not applicable to Africa”? Heterogeneity o f practice, 
and the extent to which “Western” research may apply, 
is not presently a focus of research and a research 
strategy is needed to address the question.
An expanding suite o f IAEA randomized clinical 
trials does incorporate resource-sparing strategies with 
increasing attention to clinical heterogeneity and 
questions o f tolerance.'216 These trials do not pre-judge 
whether differences are relative or categorical. They 
strive for international, multi-centre and high quality 
evidence that is from, and reflects back to, the LMIC 
context. Another approach to generating evidence that 
informs debate is to construct clinical registries to
quantify practice homogeneities, heterogeneities, and 
some determinants o f  variance. Many countries have 
pathological registries for cancer incidence. In HIC 
some registries have mortality data' 12 but most have 
few or no clinical data; and where a few Staging and 
treatment variables are captured14 ", the completeness 
and validity o f those data in HIC are being challenged.21 
Limited studies with proto-registries in Nigeria" 4 and 
Malawi23 have simulated advocacy for national plans to 
prevent and manage cancer, but most LMIC have no 
registries, or just pathology registries.2'6"4"2 Without 
current survival data in LMIC, the World Health 
Organization used modelling to convolute “Western” 
outcomes data with LMIC incidence data from some 
countries to estimate survival for LMIC."6 The accuracy 
of such high-level projections cannot be checked 
without clinical registry data arising at points o f patient 
contact, in relevant contexts. Unfortunately, recent 
international registry-based publications have few 
African contributions." ~s The 2011 IARC Volume II 
report" includes only three African data-sets (for The 
Gambia, Kenya and Zimbabwe) for mortality in just 
over 3,000 patients and who were diagnosed back in 
1993-1997. Although Stage was an optional data field 
for extraction, it was not reported for these African 
countries. To identify today's clinical policies and 
treatments by centre, country and continent, and to 
quantify any heterogeneities, we need an efficient,
standardized and systematic approach to clinical
• . ■ »..«> registries.
Any clinical registry must be very practical, efficient 
and accurate. Current population-based cancer 
registries typically rely on manual, retrospective 
abstraction and coding from patient hospital or clinic 
records. Such databases may not be of sufficient qual ity 
to provide accurate data, nor provide adequate 
radiotherapy details to assess technology.'2 To address 
limitations of existing data collection programs, we 
designed a small feasibility project to develop a 
radiation oncology-specific registry that could capture 
patient and disease characteristics, and radiation- 
therapy details, in real-time and from treating 
physicians. By capturing reliable information on 
treatment delivery and variables that affect treatment 
decisions, patterns o f practice can be easily surveyed to 
identify gaps in service or diffusion o f technologies 
(e.g. early uptake o f new methods). Areal-time clinical 
registry, particularly if  it were extended to capture
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outcome data, would be of great interest to physicians, 
policy makers, payers and vendors, and ultimately to 
cancer patients. ”
Materials and Methods
An IAEA research methods and statistics training 
course (Ethiopia, Nov 2010)14 was attended by over two 
dozen trainees and staff in radiation sciences and 
oncology disciplines. One of us (GJ) was a faculty 
member. Students raised many beliefs, opinions and 
issues, including impediments to applying “Western” 
medicine, difficulties conducting research and practice 
reviews, and worries about pursuing a research career 
in Africa. Independent of the course and the IAEA, 
eight RO trainees were contacted to help create the AF- 
rican RES-earch (AFRES) network. We agreed to 
jointly pilot a small, real-time clinical registry. For this 
p ro s p e c t iv e  o b s e rv a t io n a l  s tu d y , w ith  no 
randomization, and no funding, a short protocol was 
written with a 1-page data collection form. This was 
not a formal project of the IAEA or part of any IAEA 
training course.
Main hypotheses were that practices would differ 
and that cases in Africa would, to be consistent with 
what are apparently consensus beliefs” 104 (1) have 
higher clinical Stages; (2) receive more fractions of 
radiation per course of treatment; and (3) follow 
reasonable treatment strategies, but that some women 
with breast cancer in Africa might receive more 
extensive surgeries (mastectomy and axillary node 
d is s e c tio n )  and no t re c e iv e  T a x a n e -b a sed  
chemotherapies.
Each trainee in Radiation Oncology (three in Africa) 
and one staff Radiation Oncologist (in Canada) 
documented patient, disease and treatment data for 
their own consecutive curative and palliative cases. 
The single-use form contained absolutely no patient- 
identifiers. Check-box lists for the requested items 
included patient characteristics (age decade e.g. 30-39 
years, gender), diagnoses and pathologic features, 
Stages (for breast, rectum and prostate cancer), surgery 
and systemic therapies, and radiation details (plan type, 
dose and fractions). Writing was required for only the 
three dates (consult, and radiation start and end, else 
“pending”).
The form was designed for single-use at one time- 
point (near or at completion o f all acute treatment, or 
upon a decision against radiation treatment). We 
specifically chose this time-point as the patient changes 
phase from treatment to survivorship as a critical time 
when front-line staff is making decisions and 
maximum effort is being made by them to assemble 
data for decision-making and clinical documentation. 
This presents an opportune time to acquire data that is 
more accurate and complete. There were no repeat 
measures as only one form was completed once per 
case, so this is a study with cross-sectional design. 
There was no patient selection; all consecutive cases
with the requisite diseases o f breast, lung, rectal or 
prostate cancer were included in the study. Forms were 
submitted systematically (one per patient when 
completed at the one important time-point where data 
were readily available) to the Data and Methods Centre 
in Ontario. No forms or data were dropped from 
analysis.
Data were analyzed with STATA version 12 (College 
Station TX). Cases were grouped according to clinical 
context (e.g. curative), disease type (e.g. breast cancer), 
and participating centre (AF1, AF2, AF3, and ONI). 
We assessed how complete were data submissions to 
the proto-registry using the single-use, 1-page form. 
Data range and consistency checks were performed to 
ensure data integrity. To test the main hypothesis that 
practices would differ in (1) clinical Stages; (2) number 
o f fractions o f radiation per course o f treatment; and (3) 
treatment strategies, e.g. surgeries (mastectomy and 
ax illa ry  node d issec tio n ) and Taxane-based 
chemotherapies, Chi-squared and Fischer's Exact Tests 
were conducted. Since age-decade was collected, no 
standard error or standard deviation is reported with 
mean age. Statistical significance means a two-tailed p- 
value less than 0.05.
Participants obtained local ethics approval. The 
forms contained no patient identification; therefore all 
local ethics committees decided that neither verbal nor 
written patient consent was required. The study was 
open from December 24, 2010, to May 1, 2011, but 
some centres obtained ethics approval part-way 
through this time window for participation, so accrual 
was more limited in those centres, as their participation 
began after their respective ethics approvals were 
obtained. The simple goal was to acquire data on 
consecutive patients. Investigator-centered data from 
single individuals at only four institutions cannot be 
representative o f all practices and case-mixes in those 
institutions and countries (Sudan, South Africa. 
Zimbabwe, and Canada), but they can provide a 
window on activities and fulfill the requirements o f a 
pilot, feasibility study.
Results
Patient and disease-context variables are presented 
(Table I) for 107 forms submitted (one per patient): 62 
from the three African centres (A F1, AF2 and AF3) and 
45 from the Ontario centre (ON 1). Mean age was 54.1 
yr, differing by centre (p = 0.002, older in ON 1). The 
most common diagnosis was breast cancer (56%) and 
so 65% of all 107 cases were female, sex differing by 
centre (p < 0.0005). In ascending order, mean ages 
were breast 48, rectum 57, lung 61, and prostate 65 yr.
Cent AfrJMed  2011:57(912) 51











Mean age (yr) 47.0 45.0 58.6 59.1 54.1
Gender:
Female 17 16 4 33 70
Male 3 4 18 12 37
Breast:
Curative 14 10 0 27 51
Palliative 3 5 0 1 9
Rectum:
Curative 0 0 8 4 12
Palliative 1 2 2 0 5
Prostate:
Curative 0 0 7 3 10
Palliative 1 2 5 1 9
Lung:
Curative 0 0 0 0 0
Palliative 1 1 0 5 7
Other:
Palliative 0 0 0 4 4
There was no statistical difference by centre in the 
proportion o f cases managed with curative intent (p =
0.24). There were 73 curative (51 breast, 12 rectal and 
10 prostate) and 34 palliative cases (9 breast, 5 rectal, 9 
prostate, 7 lung and 4 other). These 107 cases 
experienced initial consultations by Radiation 
Oncology services between May 25,2010, and Apr 26, 
2011 (p = 0.002, differing by centre). However, only 
13 cases were seen prior to Dec 20, 2010; all 13 were 
with curative breast cancer (12 in ON 1, and 1 in A F1), 
indicative o f differing patterns o f referral for breast 
cancer, and reflecting m ore real-tim e m ulti­
disciplinary decision-making in O N I. Excluding 
breast cases there was no difference in consultation 
dates for the remaining cases (p = 0.34). Overall, 4 
cases were not offered radiation (1 curative breast in 
ONI and 3 palliative cases). The remainder o f this 
Results section provides, in sequence, findings for 
breast curative, other curative, and palliative cases.
O f 51 curative breast cases, 2 had in-situ disease 
(both in O N I) and 49 had invasive disease (AF1, AF2 
plus ON 1). Histology was 90% ductal, 6% lobular and 
4% other cancer types. As expected32 33, mean age was 
54.8 yr in ON 1 and it was lower at 41.7 yr in AF 1 and 
AF2 combined (p = 0.0017). General disease 
characteristics and treatments for the 49 invasive breast 
cases are shown (Table II).
Table II: Disease and treatment characteristics fo r  49 
curative breast breast cancer cases.
AFl AF2 ONI p value
(n=14) (n=10) (n=25)
Stage of Breast cancer
(A11M0):
Lower 3 1 16 0.003
Higher: N1-3&T4N0 11 9 9
Estrogen receptors
Positive 5 8 18 0.063 (n=48)
Negative 8 2 7
Missing 1 0 0
Local excision strategy
Lumpectomy 5 0 22 <0.0005
Mastectomy 9 10 3
Axillary dissection strategy
Sentinel Node 0 0 10 0.009
Axillary Node 14 10 14
None (elderly) 0 0 1
Any neo-adjuvant treatment
Yes 13 0 0 <0.0005
No 1 10 25
Chemotherapy (neoadjuvant
Or adjuvant)
Yes 12 10 15 0.012
No 2 0 10
Hormone treatment
Yes 5 8 15 0.089
No 9 2 10
Radiation volumes
Tangents-only 3 0 19 <0.0005
3- or 4- Field 11 10 5
None 0 0 1
Fractionation schedules
< 17 fractions 3 0 16 <0.0005(n=48)
17-20 fractions 10 8 0
>20 fractions 1 2 8
No radiation 0 0 1
As compared with O N I, in AF1 and AF2 there were 
statistically greater proportions o f cases with: greater 
Stage; extensive surgery (mastectomy and axillary 
d is s e c tio n ) ;  a p p lic a tio n s  o f  c h e m o th e ra p y  
(neoadjuvant and adjuvant); extensive volumes of 
radiation (i.e. loco-regional 3 and 4-field); and larger 
numbers o f fractions (from 18 to 25) o f radiation. 
Trends were also evident for lower proportions o f cases 
in Africa with positive Estrogen receptors and using 
hormones. Restricting the contrast to the 29 o f the 49
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invasive cases with highest Stages, statistical 
differences between African and Ontario centres 
remained (Table III); African women with higher- 
Stage breast cancer received more mastectomies, fewer 
Taxane-based chemotherapies, and more loco-regional 
radiation techniques (i.e. 3 and 4 field), but there were 
no differences in extent of axillary dissection, use of 
hormones or hypofractionation.
Table III: Comparison for only higher stage invasive 
breast cancer cases.
Treatment Onl AF1+AF2 p value
(N=9) (n=20)
% %
M a s te c to m y 11 7 8 0.0005
A x i l l a r y  d i s s e c t io n 1 0 0 1 0 0 Not significant
T a x a n e - c h e m o 6 7 15 0.010
H o r m o n e s 4 4 5 0 Not significant
3 - o r 4 -  f i e ld  r a d i a t i o n 5 5 9 5 0.009
H y p o f r a c t i o n a t i o n 3 3 15 Not significant
(< 1 7  f r a c t io n s )
There were 12 curative rectal cases (8 in AF3 and 4 in 
ONI). Cases were similar in these two centres, and 
received similar treatment regimens; 10 received neo­
adjuvant long-course chemo-radiation o f 25 fractions 
with 7 receiving a boost. However, one case (in ON 1) 
received a neo-adjuvant short-course 5-fraction 
scheme. There were 10 curative prostate cases (7 in 
AF3 and 3 in O N I). These were similar and received 
sim ilar treatm ents o f  local or loco-regional 
radiotherapy, and hormone suppression, strategies 
consistent with low, intermediate and high risk 
categories.
There were 34 palliative cases (6 in A F1,10 in A F2,7 
in AF3 and 11 in ONI) and 91% received palliative 
radiotherapy to one or more sites. Overall, 50% of the 
radiation targets were bone metastases (with or without 
spinal cord compression), 9% were brain, and 35% 
were other sites (soft-tissue including pelvis or chest). 
In the three African centres bone was the more likely 
target (15/23 cases vs. 2/11 ON 1 cases, p = 0.006) while 
soft-tissue was the more likely target in Ontario (8/11 
cases vs. 4/23 in AF 1, AF2 and AF3 combined). For 
bone, doses were appropriately 6 Gy in one fraction and 
up to 20 Gy in 5 fractions, regardless o f centre. 
However, “hi-grade palliation” was administered to 
two cases with soft-tissue disease in ONI (54 and 60 
Gy, over 6 weeks) using complex 3-D radiation 
planning with beam rotation and dynamic multi-leaf 
collimation methods.
i___________ , j
In total, the 107 forms were 99% complete in dala on"
initial submission (with the required total data fields 
numbering 1,874). Date o f initial consultation was 
missing in 3 cases and both estrogen receptor status and 
type o f chemotherapy were missing in 1 breast case. 
With a cut-off date for form submissions, some cases 
were “pending” a date for commencing radiation or 
chemo-radiation, and this was not counted as 
“missing.” Data on each form were logically consistent 
and demonstrated patterns o f care within each centre 
for disease types and treatment intents.
Discussion
The primary purpose o f this project was to assess 
feasibility o f a clinically-relevant registry that could 
document patterns o f  disease presentation and 
(radiation) oncology practice. This would allow 
com parative  analyses and q u an tif ica tio n  o f  
heterogeneities. Data capture near or at the end o f a 
course o f radiation meant that participants had requisite 
case-data on-hand to complete the 1-page form in 
under one or two minutes. Strengths o f this project are 
simplicity, consecutive cases, cross-sectional design 
that captured longitudinally emergent data (e.g. 
treatment completion), immediate relevance (i.e. data 
from 2011), and testing o f hypotheses. Local ethics 
boards did not require patient consent as this study was 
o f low risk to patients. Our findings support a relative 
homogeneity in important variables for curative rectal 
and prostate cancer, and for managing bone and brain 
metastases. However, one rectal cancer in Ontario was 
hypo-fractionated and two palliative cases with soft- 
tissue masses were managed with technically complex 
high-dose approaches in Ontario. In contrast, there 
was heterogeneity  in d isease and treatm ent 
characteristics for curative breast cancer cases, even 
treatment differences within those cases with more 
advanced Stage. Differences were observed between 
African and Ontarian centres, but AF1 used neo­
adjuvant strategies in contrast to AF2 which did not.
Given a small sample size, it was a surprise to 
discover statistically significant differences. If these 
were confirmed in a larger, wider project, they would 
need appropriate explanation.'4 Some differences may 
reflect a slow diffusion o f “Western” technologies. 
With breast cancer there are several recent changes in 
North America, to: sentinel node dissection; third- 
generation Taxane-based chemotherapies for some 
cases; more extreme hypo-fractionated radiation 
schedules, that spare radiation resources; and multi­
disciplinary discussions early on in a patient's clinical 
course.3536 Conversely, treatment differences can be 
intentional and entirely appropriate to context. 
Influencing variables may include patient preference, 
socio-cultural and economic aspects, travelling 
d is ta n c e s  o r co s ts , S ta g e -p ro g n o s tic -fa c to r  
combinations, radiation machine types and planning 
systems, and physician training and familiarity with a
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few techniques that may give equivalent clinical 
outcomes as other techniques, methods that are less 
familiar to the local physician. Investigation of 
heterogeneity can lead to three outcomes: it should 
affirm current practice differences; it should result in 
changes that increase uniformity to best practice34, or it 
should prompt research, especially randomized clinical 
trials that are timely and relevant to those participating 
in a registry.
Important limitations of this pilot project are the 
small number of participants (four) and cases (one 
hundred and seven). Findings can in no way be 
representative of general practices within the four 
institutions and countries. Participants had no 
assistance  from  program  m anagers or site- 
coordinators. This project did not set out to gain 
lo n g -te rm  data and we did not document on- 
treatment or subsequent adverse events (AE), disease 
control or survival. For the acute phase of 
management, a single process to capture data 
assembled when there is high-attention by front-line 
staff, i.e. at a critical time-point, should minimize 
missing data and maximize efficiency and accuracy. 
Critical time-points are when there are irreversible 
decisions being made (e.g. for treatment, or when 
approving complex radiation plans) or when patients 
are making key transitions (e.g. entering survivorship, 
or when experiencing an adverse outcom e). 
Extending to capturing outcome data, linking to 
pathology and death registries, and merging in some 
health record and treatment planning details from 
respective soft-ware sources, could be considered. 
Electronic form(s) with internal validation and direct e- 
mail submissions with automated aggregation at a data 
centre would improve on our pilot study.
A robust, real-time clinical registry (i.e) a true 
technology, a product and process, to assist font-line 
practitioners' —could have many benefits that align 
with the goals of the IAEA, including building a broad 
infrastructure for loco-regional studies, training in 
loco-regional contexts, evolving evidence-based 
practices in Radiation Oncology, and in-country 
advocacy. Most important, Radiation Oncologists 
with little academic and research infrastructure could 
easily participate for just a few minutes a day. A 
clinical registry can document practice consistency, 
treatment methods, effectiveness, applications of 
guidelines, and research-relevant skills (e.g. form 
completion, follow-up, recording AE). These would 
fulfill probationary requirements to participate in 
multi-centre, international trials. Data aggregation and 
analysis can be centralized, using software to automate 
analyses and reporting, and to assure reproducibility. 
Regular reports to participants can provide materials 
and visuals for local presentations, training o f staff, 
discussions on policies, and advocacy. Some 
participants could proceed to publications. Training in 
research methods and statistics “in context” (i.e. in 
daily practice) is known to be more efficient and 
complete, with a greater level o f transfer into local
practice, reflection and research.3'" A registry could 
also provide supplementary documentation for 
external auditing (e.g. Quality Assurance Team for 
Radiation Oncology34), or hospital accreditation, and 
international organizations could avoid relying, on 
modelling,36 historical data,27 or “pulse-taking” surveys 
to obtain a sense of current patterns of practice. 
Regarding surveys, practice within North America and 
Europe is reverting to using hypo-fractioned, shorter 
courses of radiotherapy, based on results from 
“Western” randomized trials: 16 instead o f 25 fractions 
for breast cancer4" and 5 instead o f 25 fractions for some 
rectal cancers.41 To justify two on-going randomized 
trials in LMIC1' 16 of the agency staff had to conduct 
surveys of potential investigators to assess uptake or 
interest in hypo-fractionation—for breast in 2005 and 
for rectum in 2008, because there were no summarizing 
data from international clinical registries. Our pilot 
registry, in 2011, confirms that these two studies 
remain relevant for the context o f at least a few 
countries in Africa.
Future steps are to scale-up this pilot clinical registry. 
Secondary research questions include how the process 
o f participation and practice-feedback improves 
clinical care and research infrastructure. Can clinical 
registries with current data accelerate local and 
international research relevant to LMIC? Ultimately, a 
good balance must be struck between adopting H1C or 
“Western” evidence and generating LMIC evidence 
and this requires correcting the present asymmetry of 
data collection (in 2011: more in HIC; less in LMIC). A 
relatively inexpensive continuous clinical registry, or 
one conducted in periodic waves, is a good start.
Acknowledgements
Na Yae Kim, Clinical Research Assistant at Credit 
Valley Hospital, did data-management and helped 
edit this manuscript.
References
1. Hanson GP, Stjemsward J, Nofal M, 
Durosinmi-Etti F. An overview o f the 
situation in radiotherapy with emphasis on 
the developing countries. Int J  Radiat Oncol 
BiolPhys 1990; 19(5): 1257:61.
2. E ngel -H ills  PC. R ad iation  therap ist 
research in Africa: overcoming the barriers 
to reap the rewards. J  Radiother Prac 
2009;8:93-98.
3. Levin CV, El Gueddari B, Meghzifene A. 
Radiation therapy in Africa: distribution a n d  
e q u i p m e n t .  R a d i o t h e r  O n c o l  
1999;52(l):79-84.
4. Nwogu CE, Ezeome EE, Mahoney M, 
Okoye I, Michalek AM. Regional Cancer 
con tro l in sou th  E aste rn  N igeria : a 
p r o p o s a l  e m a n a t i n g  f r o m  U I C C -
Cent Afr J  Med 2011 ;57(9/l 2) 54
sponsored workshop. West A fr  J  M ed  
2010;29(6):408-11.
5. Okobia MN. Cancer Care in sub-Saharan 
Africa-Urgent Need for Population based 
Ca nc e r  Regi s t r i es .  E th io p  J  H ea lth  
2003;17:89-98.
6. Boyle P, Levine B (Eds). World Cancer 
Report 2008. International Agency for 
Research on Cancer (IARC) Publications. 
Accessat< http://www.Iarc.fr/en/
Publications/ pdfs- online/Wcr/2008/ 
wcr 2008.pdf>
7. Akinwande O, O gundiran T, A karolo- 
Anthony S, Mamadu I, Dakum P, Blattner 
W, e t  a l .  C h a l l e n g e s  in t r e a t i n g  
malignancies in HIV in Nigeria. Curr Opin 
Oncol 2009;21 (5):455-61.
8. Sharma V, Kerr SH, Kawar Z, Kerr DJ. 
Challenges o f cancer control in developing 
count r i es :  cur r ent  s ta tus  and future  
p e r s p e c t i v e .  F u t u r e  O n c o l  
2011 ;7(10): 1213-22.
9. Lingwood RJ, Boyle P, Milbum A, Ngoma 
T, Arbuthnott J, McCaffrey R, et al. The 
challenge o f cancer control in Africa 
Perspectives. Nat Rev Cancer 2008;8:398- 
403.
10. M orris K. Cancer? In Africa? Lancet 
Oncol 2003 ;4(1):5.
11. Williams M, Wakehamb K. Radiotherapy 
might not be the answer in Africa. Lancet 
<9«co/2006;7(9):705.
12. Such opinions were put forward in the 
plenary session and discussion regarding t h e 
nature and the role of evidence, and the 
types o f equipment required in developing 
countries. International Conference on 
A d v a n c e s  in R a d i a t i o n  O n c o l o g y  
(ICARO). 27-29th April, 2009. Vienna, 
Austria.
13. African Regional Cooperative Agreement 
for Research, Development & Training 
related to Nuclear Science & Technology 
(AFRA). Regional training course on Clinical 
Trials, 15-19th May 2006, Darkar, Senegal.
14. African Regional Cooperative Agreement for 
Research, Development & Training related 
to Nuclear Science & Technology (AFRA). 
Regional training course on methodology of 
Clinical Research in Radiation Oncology, 30 
Nov 4 Dec 2010, Addis Ababa, Ethiopia.
15. Internat ional  Atomic  E nergy Agency.  
Resource-Sparing Curative Treatment for 




16. Internat ional  Atomic  Energy Agency. 
R e s o u r c e - S p a r i n g  P o s t - m a s t e c t o m y  
Radiotherapy in Breast Cancer. Access at:
<http://clinicaltrials.gov/ct2/show/NCT0145 
2 6 7 2 ? t e r m = R e s o u r c e - S p a r i n g + P o s t -  
mastectomv+Radiotherapy+in+Breast+Canc 
er&rank= 1 >
17. North American Association o f Central Cancer 
R e g i s t r i e s  ( N A A C C R ) .  N A A C C R  
Research Publications List: Multi-Registry 
Cancer Incidence and Mortality Studies in the 
United States and Canada. October 2010. 
Access at: <http://Www.naaccr.org/ 
LinkClick.Aspx?fileticket=tuvNTIeC6oO% 
3d&tabid=95&mid=477 >
18. A s an  e x a m p l e  f r o m  S u r v e i l l a n c e  
Epidemiology and End Results (SEER). 
Fairfield KM, Lucas FL, Earle CC, Small 
L, Trimble EL, Warren JL. Regional variation 
in  c a n c e r - d i r e c t e d  s u r g e r y  a n d  
mortality among women with epithelial 
ovarian cancer in the Medicare population. 
Cancer 2010;116(20):4840-8.
19. Sail K, Franzini L, Lairson D, Du X. 
Differences in treatment and survival among 
African-American and Caucasian women with 
early stage operable breast cancer. Ethn Health 
2011 N ov 9. [Epub ahead o f  print], 
DOI:10.1080/13557858.2011.628011.
20. Kiderlen M, Bastiaannet E, Walsh PM, 
Keating NL, Schrodi S, Engel J, et al. Surgical 
treatment o f early stage breast cancer in 
elderly: an international comparison. Breast 
Cancer Res Treat 2012;132(2):675-82.
21. Jagsi R, Abrahamse P, Hawley ST, Graff JJ, 
Hamilton AS, Katz SJ. Underascertainment o f 
r ad i o t herapy  rec e ip t in su rv e illa n ce , 
epidemiology, and end results registry data. 
Cancer 2012; 118(2):333-41.
22. Awodele O, Adeyomoye AA, Awodele DF, 
Fayankinnu  VB, D olapo DC. C ancer 
distribution in south-western Nigeria. Tanzan 
J  Health Res 2011; 13(2): 106-108.
23. Mlombe Y, Othieno-Abinya N, Dzamalala C, 
Chisi J. The need for a national cancer 
p o l i c y  in Ma l a wi .  M a l a w i  M e d  J. 
2008;20(4): 124-7.
24. Parkin DM, Ferlay J, Hamdi-Cherif M, Sitas F, 
Thomas JO, Wabinga, H et al. Cancer in 
Africa: Epidemiology and Prevention. IARC  
SciPubl 2003;(153): 1-414.
25. Devita VT, Lawrence TS, Rosenburg SA. 
Cancer: Principles and Practice of Oncology. 
9th ed. Philadelphia: Lippincott, Williams & 
Wilkins, 2011: Chapter 23.
26. Mathers CD, Boschi-Pinto C, Lopez AD, 
Murray CJL. Cancer incidence, mortality and 
survival by site for 14 regions of the world. 
Global Programme on Evidence fo r  Health 
Policy Discussion. In: Global Programme on 
Evidence for Health Policy Discussion. 
2001; 13(13).
27. Sankaranarayanan R, Swaminathan R, Lucas
Cent Afr J  Med 2011 ;57(9/l 2) 55
E. Cancer survival in Africa, Asia, the 
Caribbean and Central America (SurvCan). 
IARC Sci Publ 2011; 162.
28. Center MM, Jemal A. International Trends in 
Liver Cancer Incidence Rates. Cancer 
E p i d e m i o l  B i o m a r k e r s  P r e v 
2011 ;20( 11 ):2362-8.
29. Serfass L, Van Herpen C, Saghatchian M. 
Cancer Control in Africa. Euro J  Cancer 
2007;43( 10): 1493-5.
30. Bentzen SM, Constine LS, Deasy JO, Eisbruch 
A, Jackson, Marks LB, et al. Quantitative 
Analyses o f Normal Tissue Effects in the 
Clinic (QUANTEC): An Introduction to the 
Scientific Issues. In tJR adia t Oncol Biol Phys 
2010;76(3):S3-S4.
31. Palta JR, Efstathiou JA, Bekelman JE, Mutic 
S, B ogardus CR, M cN utt TR et al. 
Developing a national radiation oncology 
registry: from acoms to oaks. Prac Rad Oncol 
2012;2:10-17.
32. Mutuma GZ. Histo and Cyto-pathological 
diagnoses at a Rural Hospital in Kenya. East 
A frM ed J2001;78(5):229-232.
33. Ami r  H, Ki t inya JN, Parkin  DM. A 
comparative study o f carcinoma o f the breast 
in an African Population. East A fr M ed J  
1994;71(4):215-8.
34. Mackillop WJ. Health services research in 
Radiation Oncology. 3rd ed. In: Gunderson L, 
Tepper J, ed itors. Cl inical  R ad iation  
Oncology, Philadelphia: PA Elsevier, 2012; 
Chapter 11.
35. Wright FC, De Vito C, Langer B, Hunter A; 
The Expert Panel on Multidisciplinary Cancer 
Conference Standards. M ultidisciplinary 
cancer conferences: a systematic review and
development o f practice standards. Eur J  
Cancer 2007;43(6): 1002-10.
36. Gagliardi AR, Wright FC, Davis D, McLeod 
R S , U r b a c h  D R .  C h a l l e n g e s  in 
multidisciplinary cancer care among general 
surgeons in Canada. BMC Med Inform Decis 
Mak. 2008 Dec 22;8:59.
37. Integrating Research, Education, and Problem 
Solving: IREPS 2012, Second International 
Symposium, M arch 25th-28th, Orlando 
Fl or i da ,  USA.  D e ta ils  p r ov i de d  in: 
Callaos N, 2008. The Essence o f  Engineering 
a n d  M e t a - E n g i n e e r i n g :  A Work in 
P r o g r e s s .  A c c e s s  a t :  
< h t t p : / / w w w . i i i s . o r g / N a g i b -  
C a l l a o s / E n g i n e e r i n g - a n d - M e t a -  
Engineenng/>.
38. Ormrod JE. Motivating Students to Leam and 
A chieve. In: E ducational Psychology: 
Developing Learners. 2nd ed. Upper Saddle 
River, NJ: Merrill, 1998;498-99.
39. Quality Assurance Team for Radiation 
Oncology (QUATRO). Comprehensive Audits 
o f Radiotherapy Practises: A Tool for Quality 
Improvement 2007. International Atomic 
Energy Agency Scientific & Technical 
Publications.
40. Whelan TJ, Pignol J, Levine MN, Julian JA, 
MacKenzie R, Parpia S, et al. (2010) Long- 
Term Results o f Hypofractionated Radiation 
Therapy for Breast Cancer. N  Engl J  Med 
2010;362:513-520.
41. Swedish Rectal Cancer Trial. Improved 
survival with preoperative radiotherapy in 
resectable rectal cancer. N  Eng J  Med 
1997:336(21); 1539.
Cent Afr J  Med 2011 ;57(9/l 2) 56
This work is licensed under a 
Creative Commons
Attribution -  Noncommercial - NoDerivs 3.0 License.
To view a copy of the license please see: 
http://creativecommons.org/licenses/by-nc-nd/3.0/
This is a download from the BLDS Digital Library on OpenDocs
http://opendocs.ids.ac.uk/opendocs/
Institute of 
Development Studies
